Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma
Sponsor: Yang Li
Summary
This clinical trial aims to explore and evaluate the efficacy and safety of combined chemotherapy with arsenic trioxide for stage 4/M neuroblastoma.
Official title: Clinical Research on Efficacy and Safety of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma：A Prospective，Single-arm, Open-label, Multi-center Study
Key Details
Gender
All
Age Range
Any - 14 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2017-06-12
Completion Date
2028-12-30
Last Updated
2025-05-21
Healthy Volunteers
No
Conditions
Interventions
Arsenic Trioxide
Arsenic trioxide（ATO） is administered 0.16mg/kg per day over eight hours IV daily for ten days. Patients will receive ATO alone on days 1-2 and combined with conventional induction chemotherapy on days 3-10. Nine cycles at most of ATO-combined chemotherapy were applied in the whole scheme.
Locations (1)
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China